Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Grützmacher

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Research in Cardiology Supplements|August 23, 2012
Lipid apheresis techniques: current status in GermanyPeter Grützmacher, Claudius Kleinert
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresisReinhard Klingel, Franz Heigl, Volker Schettler, et al.
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?Franz Heigl, Tobias Pflederer, Reinhard Klingel, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
European Heart Journal|May 19, 2026
Lipoprotein apheresis in the era of new lipid-lowering therapiesFrancesco Sbrana, Beatrice Dal Pino, Volker J J Schettler, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Research in Cardiology Supplements|August 23, 2012
Lipid apheresis techniques: current status in GermanyPeter Grützmacher, Claudius Kleinert
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresisReinhard Klingel, Franz Heigl, Volker Schettler, et al.
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?Franz Heigl, Tobias Pflederer, Reinhard Klingel, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
European Heart Journal|May 19, 2026
Lipoprotein apheresis in the era of new lipid-lowering therapiesFrancesco Sbrana, Beatrice Dal Pino, Volker J J Schettler, et al.
Pageof 1